During the COVID-19 emergency, the Food and Drug Administration will not take action in certain circumstances against a registered outsourcing facility for compounding certain drugs to treat hospitalized patients with COVID-19; using a bulk drug substance not on the 503B bulk list; or not meeting current good manufacturing process requirements, the agency announced today.

“Many hospitals are currently experiencing difficulties accessing FDA-approved drug products used for patients with COVID-19,” the agency said. “…[I]n light of unprecedented disruptions to, and demands on, the global pharmaceutical supply chain as a result of the COVID-19 pandemic, and in order to respond to evolving regional conditions, additional flexibility is temporarily needed to ensure that treatment options are available when hospitals are unable to obtain FDA-approved drugs used for hospitalized patients with COVID-19."

Related News Articles

Headline
The Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee today by a unanimous vote recommended that the FDA issue an…
Perspective
For nearly 20 grueling months, hospitals and health systems — and their steadfast front-line caregivers — have risen to the incredible challenges caused by…
Headline
The Centers for Disease Control and Prevention today revealed the comparative effectiveness of the three Food and Drug Administration-authorized COVID-19…
Headline
The Centers for Disease Control and Prevention will invest $2.1 billion from the American Rescue Plan Act to help public health and other partners fight COVID-…
Headline
The Department of Health and Human Services’ Assistant Secretary for Preparedness and Response this week announced a major change in the distribution of…
Headline
The AHA has received a $1 million grant from the Centers for Disease Control and Prevention to continue for one year its efforts to encourage COVID-19…